Littlejohn, Geoffrey http://orcid.org/0000-0002-7896-055X
Leadbetter, Joanna
Butcher, Belinda E. http://orcid.org/0000-0002-1415-4065
Feletar, Marie
O’Sullivan, Catherine http://orcid.org/0000-0003-0564-9768
Smith, Tegan http://orcid.org/0000-0002-2944-9712
Witcombe, David http://orcid.org/0009-0001-7213-9461
Ng, Ho Yin http://orcid.org/0000-0002-3432-4981
Youssef, Peter http://orcid.org/0000-0002-9010-3999
Funding for this research was provided by:
Pfizer Australia
Monash University
Article History
Received: 23 November 2023
Revised: 29 February 2024
Accepted: 1 March 2024
First Online: 9 March 2024
Declarations
:
: The activities of OPAL Rheumatology Ltd have received overarching ethics approval from the University of New South Wales (UNSW) Human Research Ethics Committee (HREC), based on a patient opt-out arrangement (HC17799).
: This research protocol was approved by the UNSW HREC (HC200786). Opt-out arrangement for consent for research involving non-reidentifiable routine electronic medical records.
: Patients have consented to the publication of data on an opt-out basis. All data are de-identified.
: COS and TS are employees of OPAL Rheumatology Ltd and declare no competing interests. JL and BB are independent statistical consultants, funded by OPAL. The following interests are declared for GL; Astra Zeneca, MF; AbbVie, Janssen, UCB, Pfizer and Lilly and PY; Abbvie, Eli Lilly, Celltrion, Pfizer, Sandoz. DW and HN are employees of Pfizer.